Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of POL7080 in Renal Impairment
NCT02110459Phase 1Completed
- Sponsor
- Polyphor
- Start
- Apr 2013
- Primary completion
- Jul 2015
- Modality
- Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of murepavadin in Pseudomonas aeruginosa infection (6 arms), sponsored by Polyphor. Primary endpoint: Plasma concentrations of POL7080 at 75 hours. Started Apr 2013; status: completed.
02
Drugs
murepavadin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02110459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110459.